Liquidia (NASDAQ:LQDA) Stock: Insider Scott Moomaw Sells 8,863 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 8,863 shares of the business’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $252,418.24. Following the sale, the insider directly owned 181,487 shares in the company, valued at approximately $5,168,749.76. This trade represents a 4.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Price Performance

LQDA opened at $33.94 on Thursday. The stock has a fifty day moving average of $62.30 and a 200-day moving average of $61.74. The firm has a market capitalization of $3.04 billion, a P/E ratio of 24.77 and a beta of 0.61. Liquidia Corporation has a 12-month low of $21.94 and a 12-month high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. During the same period last year, the business earned ($0.49) EPS. The business’s quarterly revenue was up 1842.1% on a year-over-year basis. Equities analysts forecast that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The settlement allows Liquidia to continue commercializing YUTREPIA for pulmonary arterial hypertension (PAH) without interruption, removing a major source of legal and commercial uncertainty. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, contributing to $396.1 million in cash and equivalents. Management said it expects ongoing sales and existing cash to fund settlement obligations and clinical programs without additional financing. RTTNews settlement report
• Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA from “neutral” to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” and set a $59 target. Needham maintained “buy” but lowered its target to $58.
• Positive Sentiment: Trading activity reflected strong investor interest, with call-option volume more than doubling its average level.
• Neutral Sentiment: Liquidia agreed to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to the antitrust litigation. The payments resolve the disputes but will significantly draw down cash.
• Negative Sentiment: The company will not appeal the patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential revenue opportunities. Zacks settlement analysis
• Negative Sentiment: Multiple executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the sales were planned and left executives with substantial holdings, they are a limited standalone signal, but broader insider activity remains heavily weighted toward selling.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its stake in shares of Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after buying an additional 360,372 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Liquidia in the second quarter worth $29,694,000. Eversept Partners LP increased its stake in shares of Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after acquiring an additional 167,949 shares during the last quarter. Seven Fleet Capital Management LP increased its stake in shares of Liquidia by 25.2% in the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after acquiring an additional 51,727 shares during the last quarter. Finally, Pale Fire Capital SE raised its holdings in shares of Liquidia by 2.4% during the first quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock worth $14,657,000 after acquiring an additional 8,985 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

LQDA has been the subject of several research analyst reports. BTIG Research raised Liquidia from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Wednesday. Bank of America lifted their target price on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Piper Sandler set a $129.00 target price on Liquidia in a report on Friday, July 24th. Citigroup reiterated a “neutral” rating on shares of Liquidia in a report on Thursday, October 1st. Finally, Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Liquidia presently has a consensus rating of “Hold” and an average price target of $77.31.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).